Preciseli Cancer. An individualized approach to cancer prevention.

Through a deep understanding of an individual’s genetics,
lifestyle, and environmental factors we can provide a proactive
and personalized plan to prevent cancer from happening in the first place.

We have a chance to radically improve the accuracy, efficiency, timeliness (early) of detection and cost effectiveness for cancer screening by multiple means.

Eric Topol

Physician-scientist, Author

The realities of cancer.

At Preciseli, we use comprehensive genomic risk stratification to tackle the most important issues in cancer prevention.

We are not all the same

Current screening guidelines based on population health models assume all individuals have "average" risk and therefore prescribe the same cancer prevention screening strategies for many.

We will all be affected by cancer

The American Cancer Society (ACS) estimates that approximately 1 in 2 men (50%) and 1 in 3 women (33%) are estimated to develop cancer at some point in their lifetime. ¹

Cancer is trending younger

Recent studies have shown a concerning trend of breast, colorectal, and other cancer diagnoses occurring more frequently in younger individuals and current screening guidelines don’t address this growing fact. ¹

Early cancer detection is the key.Cancer survival largely depends on the stage at which a cancer is diagnosed.³

Survival Rate

21%

Stage III and IV
has a 21% survival rate.

89%

Stage I and II
‍has an 89% survival rate.

Preciseli Cancer

Making personalized cancer prevention the new reality.

Preciseli cancer revolutionizes how we look at cancer risk by leveraging our proprietary advancements in genome-based risk assessment, enhanced by our cutting-edge predictive modeling and machine learning algorithms.

Computational Models

Large genomic datasets have accelerated our ability to understand and thereby model how genetic predispositions impact an individual’s risk for disease.

Genomics at Scale

Our innovations in advanced bioinformatics and the decreasing cost of DNA sequencing allows us to democratize access to advanced cancer prevention strategies.

Multi-cancer Early Detection

For those with the highest risks for cancer, Preciseli paves a simple, but potentialy life-saving pathway to multi-cancer early detection technology promising better patient outcomes and survival rates.

Preciseli

Informed by Science. Driven by Innovation.

Preciseli’s platform is the culmination of years of rigorous scientific research in genomic risk stratification and personalized medicine.

Translational Research

At Preciseli, we bridge the gap between cutting-edge research and clinical practice with a platform built upon a foundation of rigorous scientific inquiry and supported by years of dedicated research and NIH funding in genomic risk stratification and personalized medicine.

Clinical Algorithms

Our clinical algorithms are developed in collaboration with leading researchers and clinicians, and harness the power of genomic insights to understand cancer risk and guide personalized care pathways.

Innovation

Preciseli continually push the boundaries of possibility, pioneering new approaches to genomic risk assessment and personalized medicine. With a steadfast commitment to advancing the field of oncology, Preciseli leads the way in revolutionizing cancer prevention and early detection through innovation-driven solutions

Have questions? We have answers.

Want to know more? Here is a collection of our most commonly asked questions.

How does Preciseli generate PRS?

A polygenic risk score (PRS) is calculated for colon cancer, breast cancer (females), and prostate cancer (males) individually and is a summary of genetic risk from hundreds of common genetic variants. Each genetic variant makes a small contribution to your overall risk. The cumulative contribution of these genetic variants can put you at high genetic risk for common diseases. Most people have average genetic risk. To generate PRSs, we apply state of the art computational techniques to identify these genetic variants in your genome, add up their contributions to your individual genetic risk, and return your summarized risk as a polygenic risk score.

Is Preciseli Diagnostic?

No, Preciseli does not diagnose any health conditions. While having particular genetic variants can be linked to a higher or lower risk for a condition, it does not necessarily mean you will or won’t develop that condition. It is also important to remember that these reports may not cover all possible genetic variants that could influence risk, as research for these variants is ongoing. As you’ll discover, environment and lifestyle can also influence risk for these conditions. Our coaches may recommend that you consult with your primary care physician if the health risks uncovered by Preciseli require it. Additionally, if you have a high genetic risk for a particular cancer, Preciseli may recommend a yearly liquid biopsy which checks for cancer in your body from a blood sample.

What will Preciseli’s platform tell me?

Preciseli's platform uncovers health risks that you may or may not have previously been aware of. We help you interpret those risks holistically and provide suggestions and guidance on how to most effectively deal with your specific risks.

SOURCES

American Cancer Society
American Cancer Society
SEER Stat Database. 5-year survival data. Incidence for persons aged 50-79 diagnosed 2006-2015"